Pfizer filed a second lawsuit against Metsera, Novo Nordisk, and others, alleging Novo's bid to acquire Metsera is an anticompetitive move to block competition in GLP-1 drugs. Pfizer seeks to halt the transaction through injunctive relief. The filing follows Novo's unsolicited offer, which challenges Pfizer's earlier agreement to buy Metsera.